The U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday upheld the District of Delaware’s grant of judgment as a matter of law (JMOL) that Amgen’s patent claims covering its Repatha cholesterol treatment were invalid for lack of enablement. The court found that Amgen’s composition claims were defined by meeting functional limitations, rather than by structure, and that the patent specifications didn’t enable the preparation of the full scope of the claims without undue experimentation. Judge Lourie authored the opinion. Amgen v. Sanofi (CAFC, Feb. 11, 2020)
Recent Posts
- Amid Approval of EU AI Act, Creators Demand Stronger Protections for Rightsholders
- CAFC Affirms District Court’s Inventorship Analysis
- Responding to Obviousness Rejections in Light of the USPTO’s New Guidance
- High-Tech Groups and EFF Revive Patent Troll Narrative and Other Lies
- Vidal Delays OpenSky Payment But Upholds Attorney’s Fees Award for VLSI